Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuts health claim OK’ed

This article was originally published in The Tan Sheet

Executive Summary

FDA affirms first qualified health claim under "Interim Evidence-Based Ranking System for Scientific Data" guidance published in July 11 Federal Register (1"The Tan Sheet" July 14, 2003, p. 3). The claim will allow manufacturers of peanuts, almonds, walnuts and other nuts to say that "scientific evidence suggests but does not prove" that eating 1.5 oz in conjunction with a diet low in saturated fat and cholesterol "may" reduce the risk of developing heart disease...

You may also be interested in...

Qualified Health Claims Scientific Evidence To Be Assessed, Ranked By FDA

FDA will rank qualified health claims for use on dietary supplement and food products based on an evaluation of the scientific evidence that supports them, according to guidelines announced July 10

ACA Ruling Is Double Whammy For PrEP Coverage, With Contraception And Vaccines Still At Risk

 Obamacare’s affordable access to HIV pre-exposure prophylaxis is jeopardized by court order. Access to vaccines, contraception may also be at risk as the case continues to play out in higher courts. 

US Infant Formula Supply Chain Strategy Delivered

FDA immediate actions include ensuring providers know they’re required to develop redundancy risk management plans, enhancing inspections of manufacturers, including by expanding and improving training for investigators, and expediting reviews of premarket submissions for new products.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts